| Japanese |
|---|
| Title | 131I標識抗α-fetoprotein (AFP) 抗体を用いた肝癌免疫イメージング |
|---|
| Subtitle | 研究速報 |
|---|
| Authors | 小泉潔*, 油野民雄*, 横山邦彦*, 渡辺直人*, 川畑鈴佳*, 秀毛範至*, 向加津子*, 利波紀久*, 久田欣一*, 田中延善**, 泉良平***, 高橋豊**** |
|---|
| Authors(kana) | |
|---|
| Organization | *金沢大学医学部核医学教室, **第一内科学教室, ***第二外科学教室, ****金沢大学がん研究所外科部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 23 |
|---|
| Number | 4 |
|---|
| Page | 397-401 |
|---|
| Year/Month | 1986/4 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「I. 緒言」腫瘍特異抗原や関連抗原に対する抗体を放射性核種により標識して体内に投与し, その腫瘍の局在をイメージングによって検索しようという放射免疫イメージング(Radioimmunoimaging)は, 腫瘍を特異的に描出しうるという点において大きな注目を集めている. さらに近年のモノクローナル抗体(MoAb)作製手技の向上に伴い, それを応用した報告は枚挙にいとまない. 肝細胞癌により産生されるAFPに対する抗体を用いた免疫イメージングは, ポリクローナル抗体(PoAb)を用いてすでに報告されている. 一般にPoAbによるイメージングはMoAbより劣ると考えられているが, subtraction法を用いれば抗AFP抗体イメージングでは必ずしもPoAbの成績は悪くはない. しかしながらsubtraction法は疑陽性率を増加しうるという問題点もある. そこで今回抗AFP抗体イメージング(PoAb)をsubtractionを行わず臨床的に検討を加えたので報告する. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Radioimmunoimaging, Polyclonal antibody, Anti α-fetoprotein antibody, Alfafetoprotein. |
|---|
| English |
|---|
| Title | Radioimmunoimaging of Hepatic Tumors with 131I Labeled Polyclonal Antibody against α-Fetoprotein (AFP) |
|---|
| Subtitle | |
|---|
| Authors | Kiyoshi KOIZUMI*, Tamio ABURANO*, Kunihiko YOKOYAMA*, Naoto WATANABE*, Suzuka KAWABATA*, Noriyuki SHUKE*, Katsuko MUKAI*, Norihisa TONAMI*, Kinichi HISADA*, Nobuyoshi TANAKA**, Ryohei IZUMI***, Yutaka TAKAHASHI**** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Nuclear Medicine, **Department of First Internal Medicine, ***Department of Second Surgery, ****Cancer Institute, Department of Surgery, Kanazawa University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 23 |
|---|
| Number | 4 |
|---|
| Page | 397-401 |
|---|
| Year/Month | 1986/4 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | Though monoclonal antibodies are generally considered to be superior to polyclonal antibodies in radioimmunoimaging, the superiority is controversial in anti AFP antibodies to date. Therefore, this clinical trial using one of these antibodies was conducted to evaluate its usefulness. An anti AFP polyclonal antibody labeled with 131I by lactoperoxidase was administered to patients with hepatic tumors ; 6 patients with hepatocellular carcinomas and 1 patient with metastatic liver tumor from gastric cancer. Subtraction technique was not used in this study. Out of 7 patients, three(43%) had their tumors demonstrated by immunoimaging at 6 days after injection. Serum AFP levels of these 3 patients were relatively low. The patient with the highest serum level showed very rapid clearance of the radioactivity from the body. Liver cirrhosis was complicated in 4 patients, and only 1 patient showed positive visualization of the tumor. This suggested that coexisting liver cirrhosis might obliterate the uptake of the anti AFP antibody to the hepatic tumor itself because this antibody might be also bound to cirrhotic liver. No related side effects were observed. We conclude that hepatic tumors could be visualized by radioimmunoimaging using anti AFP polyclonal antibodies without subtraction technique if the images were taken in 6 days after injection. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Radioimmunoimaging, Polyclonal antibody, Anti α-fetoprotein antibody, Alfafetoprotein. |
|---|